248 related articles for article (PubMed ID: 15371874)
1. Enhanced sensitivity of bladder cancer cells to cisplatin mediated cytotoxicity and apoptosis in vitro and in vivo by the selective cyclooxygenase-2 inhibitor JTE-522.
Mizutani Y; Nakanishi H; Li YN; Sato N; Kawauchi A; Miki T
J Urol; 2004 Oct; 172(4 Pt 1):1474-9. PubMed ID: 15371874
[TBL] [Abstract][Full Text] [Related]
2. Synergistic cytotoxicity and apoptosis of JTE-522, a selective cyclooxygenase-2 inhibitor, and 5-fluorouracil against bladder cancer.
Mizutani Y; Kamoi K; Ukimura O; Kawauchi A; Miki T
J Urol; 2002 Dec; 168(6):2650-4. PubMed ID: 12442003
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of the sensitivity of renal cell carcinoma cells to fas-mediated cytotoxicity and apoptosis by the selective cyclooxygenase-2 inhibitor JTE-522.
Sato N; Mizutani Y; Li YN; Fujiwara J; Ishida H; Toiyama D; Abe K; Hayashi I; Nakanishi H; Kawauchi A; Miki T
Urol Int; 2010; 84(3):362-8. PubMed ID: 20389170
[TBL] [Abstract][Full Text] [Related]
4. Sensitization of human bladder cancer cells to Fas-mediated cytotoxicity by cis-diamminedichloroplatinum (II).
Mizutani Y; Yoshida O; Bonavida B
J Urol; 1998 Aug; 160(2):561-70. PubMed ID: 9679929
[TBL] [Abstract][Full Text] [Related]
5. Enhanced sensitivity of bladder cancer cells to tumor necrosis factor related apoptosis inducing ligand mediated apoptosis by cisplatin and carboplatin.
Mizutani Y; Nakao M; Ogawa O; Yoshida O; Bonavida B; Miki T
J Urol; 2001 Jan; 165(1):263-70. PubMed ID: 11125422
[TBL] [Abstract][Full Text] [Related]
6. Chemoimmunosensitization of the T24 human bladder cancer line to Fas-mediated cytotoxicity and apoptosis by cisplatin and 5-fluorouracil.
Mizutani Y; Wu XX; Yoshida O; Shirasaka T; Bonavida B
Oncol Rep; 1999; 6(5):979-82. PubMed ID: 10425290
[TBL] [Abstract][Full Text] [Related]
7. Enhancement of sensitivity of urinary bladder tumor cells to cisplatin by c-myc antisense oligonucleotide.
Mizutani Y; Fukumoto M; Bonavida B; Yoshida O
Cancer; 1994 Nov; 74(9):2546-54. PubMed ID: 7923012
[TBL] [Abstract][Full Text] [Related]
8. Induction of apoptosis by JTE-522, a specific cyclooxygenase-2 inhibitor, in human gastric cancer cell lines.
Uefuji K; Ichikura T; Shinomiya N; Mochizuki H
Anticancer Res; 2000; 20(6B):4279-84. PubMed ID: 11205258
[TBL] [Abstract][Full Text] [Related]
9. The potential for a selective cyclooxygenase-2 inhibitor in the prevention of liver metastasis in human colorectal cancer.
Yamauchi T; Watanabe M; Hasegawa H; Nishibori H; Ishii Y; Tatematsu H; Yamamoto K; Kubota T; Kitajima M
Anticancer Res; 2003; 23(1A):245-9. PubMed ID: 12680220
[TBL] [Abstract][Full Text] [Related]
10. JTE-522, a selective COX-2 inhibitor, inhibits cell proliferation and induces apoptosis in RL95-2 cells.
Li HL; Zhang HW; Chen DD; Zhong L; Ren XD; St-Tu R
Acta Pharmacol Sin; 2002 Jul; 23(7):631-7. PubMed ID: 12100758
[TBL] [Abstract][Full Text] [Related]
11. Inhibitory effect of a selective cyclooxygenase inhibitor on the invasion-stimulating activity of orthotopic fibroblasts for scirrhous gastric cancer cells.
Tendo M; Yashiro M; Nakazawa K; Yamada N; Hirakawa K
Cancer Sci; 2005 Jul; 96(7):451-5. PubMed ID: 16053517
[TBL] [Abstract][Full Text] [Related]
12. Cyclooxygenase-2 gene induction causes CDDP resistance in colon cancer cell line, HCT-15.
Saikawa Y; Sugiura T; Toriumi F; Kubota T; Suganuma K; Isshiki S; Otani Y; Kumai K; Kitajima M
Anticancer Res; 2004; 24(5A):2723-8. PubMed ID: 15517878
[TBL] [Abstract][Full Text] [Related]
13. Suppression of N-nitrosomethylbenzylamine (NMBA)-induced esophageal tumorigenesis in F344 rats by JTE-522, a selective COX-2 inhibitor.
Li Z; Shimada Y; Kawabe A; Sato F; Maeda M; Komoto I; Hong T; Ding Y; Kaganoi J; Imamura M
Carcinogenesis; 2001 Apr; 22(4):547-51. PubMed ID: 11285187
[TBL] [Abstract][Full Text] [Related]
14. Combination chemotherapy with JTE-522, a novel selective cyclooxygenase-2 inhibitor, and cisplatin against gastric cancer cell lines in vitro and in vivo.
Sugiura T; Saikawa Y; Kubota T; Suganuma K; Otani Y; Watanabe M; Kumai K; Kitajima M
In Vivo; 2003; 17(3):229-33. PubMed ID: 12929571
[TBL] [Abstract][Full Text] [Related]
15. Sunitinib can enhance BCG mediated cytotoxicity to transitional cell carcinoma through apoptosis pathway.
Ping SY; Wu CL; Yu DS
Urol Oncol; 2012 Sep; 30(5):652-9. PubMed ID: 20884251
[TBL] [Abstract][Full Text] [Related]
16. Synergistic cytotoxicity and apoptosis by Apo-2 ligand and adriamycin against bladder cancer cells.
Mizutani Y; Yoshida O; Miki T; Bonavida B
Clin Cancer Res; 1999 Sep; 5(9):2605-12. PubMed ID: 10499639
[TBL] [Abstract][Full Text] [Related]
17. Involvement of the mitochondrion respiratory chain in the synergy achieved by treatment of human ovarian carcinoma cell lines with both tumor necrosis factor-alpha and cis-diamminedichloroplatinum.
Uslu R; Bonavida B
Cancer; 1996 Feb; 77(4):725-32. PubMed ID: 8616765
[TBL] [Abstract][Full Text] [Related]
18. Profile of JTE-522 as a human cyclooxygenase-2 inhibitor.
Wakitani K; Nanayama T; Masaki M; Matsushita M
Jpn J Pharmacol; 1998 Nov; 78(3):365-71. PubMed ID: 9869271
[TBL] [Abstract][Full Text] [Related]
19. MK2206 potentiates cisplatin-induced cytotoxicity and apoptosis through an interaction of inactivated Akt signaling pathway.
Sun D; Sawada A; Nakashima M; Kobayashi T; Ogawa O; Matsui Y
Urol Oncol; 2015 Mar; 33(3):111.e17-26. PubMed ID: 25499922
[TBL] [Abstract][Full Text] [Related]
20. Significant growth inhibition of human lung cancer cells both in vitro and in vivo by the combined use of a selective cyclooxygenase 2 inhibitor, JTE-522, and conventional anticancer agents.
Hida T; Kozaki K; Ito H; Miyaishi O; Tatematsu Y; Suzuki T; Matsuo K; Sugiura T; Ogawa M; Takahashi T; Takahashi T
Clin Cancer Res; 2002 Jul; 8(7):2443-7. PubMed ID: 12114451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
